Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.

Autor: Jahangir M; Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran., Yazdani O; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Kahrizi MS; Department of Surgery, Alborz University of Medical Sciences, Karaj, Alborz, Iran., Soltanzadeh S; Department of Radiation Oncology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Javididashtbayaz H; Baran Oncology Clinic, Medical Faculty, Islamic Azad University of Mashhad, Mashhad, Iran., Mivefroshan A; Department of Adult Nephrology, Urmia University of Medical Sciences, Urmia, Iran., Ilkhani S; Department of Surgery and Vascular Surgery, Shohada-ye-Tajrish Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran. Sabailkhani.si@gmail.com., Esbati R; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Romines9573@gmail.com.
Jazyk: angličtina
Zdroj: Cancer cell international [Cancer Cell Int] 2022 Dec 12; Vol. 22 (1), pp. 401. Date of Electronic Publication: 2022 Dec 12.
DOI: 10.1186/s12935-022-02816-3
Abstrakt: Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might ultimately favor cancer development in patients with clinical responses. In light of this, recent reports have signified that the addition of other therapeutic modalities to PD-1/PD-L1 blockade therapy might improve clinical responses in advanced RCC patients. Until, combination therapy with PD-1/PD-L1 blockade therapy plus cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor (ipilimumab) or various vascular endothelial growth factor receptors (VEGFRs) inhibitors axitinib, such as axitinib and cabozantinib, has been approved by the United States Food and Drug Administration (FDA) as first-line treatment for metastatic RCC. In the present review, we have focused on the therapeutic benefits of the PD-1/PD-L1 blockade therapy as a single agent or in combination with other conventional or innovative targeted therapies in RCC patients. We also offer a glimpse into the well-determined prognostic factor associated with the clinical response of RCC patients to PD-1/PD-L1 blockade therapy.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: